Neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson's disease via autophagy modulation - PubMed
5 hours ago
- #Parkinson's disease
- #DPP-4 inhibitors
- #Autophagy
- Study investigates neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson's disease (PD) models.
- In vitro, both drugs enhanced mitophagy and modulated autophagy pathways in neuronal cell lines.
- Sitagliptin promoted autophagy in Drosophila larval fat body at concentrations of 20-80 µM.
- Vildagliptin (15 mg/kg/day) reduced neuronal loss and microglial activation in an MPTP-induced mouse PD model.
- Network pharmacology identified DPP-4, AKT1, and GSK3β as key protein targets.
- Findings suggest sitagliptin and vildagliptin modulate autophagy/mitophagy, aiding clearance of pathogenic aggregates and dysfunctional mitochondria.
- Potential disease-modifying therapy for PD.